Literature DB >> 1452492

Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics.

J Liñares1, T Alonso, J L Pérez, J Ayats, M A Domínguez, R Pallarés, R Martín.   

Abstract

The in-vitro activity of 24 beta-lactam antibiotics was compared using three groups of pneumococci and an agar dilution method comprising 100 penicillin-susceptible, 100 intermediately penicillin-resistant, and 100 highly penicillin-resistant pneumococcal strains. Our results show that intermediately penicillin-resistant and highly penicillin-resistant pneumococci had decreased sensitivity to other beta-lactam agents. According to their relative in-vitro activity, the antimicrobials were classified into three groups. The first group included drugs more active than penicillin (imipenem, meropenem, cefotaxime, ceftriaxone, and cefpirome), which could be useful for the treatment of infections due to penicillin-resistant strains. The second group showed slightly lesser activity than did penicillin, and included: ampicillin, cefdinir, cefuroxime, cefoperazone, azlocillin, mezlocillin, piperacillin, cephalothin, and cefamandole. The remaining antibiotics (oxacillin, cefixime, ceftizoxime, cefetamet, cefaclor, ceftazidime, cefoxitin, cefonicid, and latamoxef) showed poor activity against penicillin-resistant strains, precluding their use for empirical treatment in areas with a high prevalence of penicillin-resistant strains.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1452492     DOI: 10.1093/jac/30.3.279

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  41 in total

1.  Comparison of agar dilution, microdilution, E-test, and disk diffusion methods for testing activity of cefditoren against Streptococcus pneumoniae.

Authors:  L M Kelly; M R Jacobs; P C Appelbaum
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

2.  Streptococcus pneumoniae: Activity of Newer Agents Against Penicillin-Resistant Strains.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

3.  Determination of penicillin susceptibility of Streptococcus pneumoniae using the polymerase chain reaction.

Authors:  H Jalal; S Organji; J Reynolds; D Bennett; E O'Mason; M R Millar
Journal:  Mol Pathol       Date:  1997-02

4.  Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

5.  In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

6.  Bactericidal activities of ceftizoxime and cefotaxime against Streptococcus pneumoniae.

Authors:  K B Waites; T Rivers
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

7.  In vitro susceptibility of 90 penicillin-susceptible and -resistant pneumococci to penicillin G, amoxicillin, amoxicillin/clavulanate, cefaclor, cefuroxime, cefpodoxime, cefixime and imipenem.

Authors:  H Hupková; J Trupl
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

8.  In vitro activity of ceftizoxime, ceftazidime, cefuroxime, ceftriaxone, cefotaxime, and penicillin against Streptococcus pneumoniae as determined by three quantitative methods.

Authors:  A L Barry; S D Brown; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

Review 9.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

Review 10.  Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.

Authors:  A Markham; R N Brogden
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.